pharmaceuticals
pharmaceuticals Articles
ContraVir Pharmaceuticals stock shot up following positive results from a hepatitis B study earlier this week, but now it is back down after the pricing of a secondary offering was announced.
Published:
Last Updated:
Long-term growth investors looking for a degree of safety and value should consider some of these outstanding companies. While the sentiment may be less than stellar now, massive drug pricing changes...
Published:
Last Updated:
Acadia Pharmaceuticals saw its shares on the rise again this week following an incredibly positive FDA vote on its Parkinson's treatment.
Published:
Last Updated:
The SEC has announced fraud charges against Aveo Pharmaceuticals and three former executives for misleading investors.
Published:
Last Updated:
ContraVir Pharmaceuticals led the bulls early on Tuesday following the release of positive hepatitis B results.
Published:
Last Updated:
BioPharmX saw its shares take a sharp downward turn following the announcement of a secondary offering.
Published:
Last Updated:
Inovio Pharmaceuticals made waves early on Tuesday morning following an update for its human papillomavirus (HPV) treatment.
Published:
Last Updated:
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
Published:
Last Updated:
Aeglea BioTherapeutics expects to price more than 3 million shares in a range of $16 to $18 per share for an initial public offering valued up to more than $72 million.
Published:
Last Updated:
Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) surged early on Monday morning. This company is under the spotlight by the U.S. Food and Drug Administration’s Psychopharmacologic Drugs...
Published:
Last Updated:
Apricus Biosciences announced top-line results from the Phase 2b proof-of-concept study of fispemifene in men with secondary hypogonadism and sexual dysfunction.
Published:
Last Updated:
Alder Biopharmaceuticals announced positive top-line data from two clinical trials evaluating its proprietary monoclonal antibody product candidate for migraine prevention.
Published:
Last Updated:
Over the past week, Akorn, Celator Pharmaceuticals and a few other biotech companies made impressive runs.
Published:
Last Updated:
Celator Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
Published:
Last Updated:
Vitae Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering valued at up to $40 million.
Published: